Heron Therapeutics Inc (HRTX)

Jun 19, 2026

Heron Therapeutics Inc (HRTX) Valuation: PE, PB & Fair Value Analysis - TradingKey

Jun 19, 2026

Jun 18, 2026

Heron Therapeutics Inc (HRTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

Jun 18, 2026

Jun 17, 2026

Heron Therapeutics Inc (HRTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Jun 17, 2026

Jun 17, 2026

Heron Therapeutics Inc (HRTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

Jun 17, 2026

Jun 17, 2026

Heron Therapeutics Inc (HRTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey

Jun 17, 2026

Jun 17, 2026

HRTX Stock Price, Quote & Chart - ChartMill

Jun 17, 2026

Jun 17, 2026

Heron Therapeutics StockShareholders back equity plans and tax measure at 2026 meeting - AD HOC NEWS

Jun 17, 2026

Jun 17, 2026

Heron Therapeutics (NASDAQ: HRTX) CFO exercises RSUs and withholds shares for taxes - Stock Titan

Jun 17, 2026

Jun 16, 2026

Heron Therapeutics Inc (HRTX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey

Jun 16, 2026

Jun 16, 2026

Heron Therapeutics Inc (HRTX) Institutional Confidence - TradingKey

Jun 16, 2026

Jun 16, 2026

Heron Therapeutics Inc (HRTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Jun 16, 2026

Jun 16, 2026

Heron Therapeutics Inc (HRTX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

Jun 16, 2026

Jun 16, 2026

Heron Therapeutics stockholders approve director slate and plan amendments at annual meeting - Investing.com

Jun 16, 2026

Jun 16, 2026

Heron Therapeutics (HRTX) holders approve board, equity share increases and tax plan - Stock Titan

Jun 16, 2026

Jun 11, 2026

HRTX: All director nominees and proposals were approved, with no questions from stockholders - TradingView

Jun 11, 2026

Jun 10, 2026

HRTX Q1 2026 Earnings: Deep EPS Miss Triggers 10.7% Stock DeclineGuidance Accuracy Score - newsline.com

Jun 10, 2026

Jun 10, 2026

Heron Therapeutics In A Tough Spot After Cinvanti Court Loss (Rating Downgrade) - Seeking Alpha

Jun 10, 2026

Jun 08, 2026

Heron Therapeutics (HRTX) EVP converts 12,500 RSUs into common shares - Stock Titan

Jun 08, 2026

Jun 08, 2026

H.C. Wainwright Maintains Heron Therapeutics(HRTX.US) With Buy Rating, Maintains Target Price $2 - Moomoo

Jun 08, 2026

Jun 06, 2026

TANG KEVIN C's Strategic Acquisition in Aurinia Pharmaceuticals Inc - GuruFocus

Jun 06, 2026

Jun 03, 2026

HRTX Maintains Buy Rating -- Price Target Lowered to $2.00 by HC Wainwright - GuruFocus

Jun 03, 2026

Jun 03, 2026

Heron Therapeutics Appeals Ruling Invalidating CINVANTI Patents - The Globe and Mail

Jun 03, 2026

Jun 03, 2026

H.C. Wainwright Maintains Heron Therapeutics(HRTX.US) With Buy Rating, Cuts Target Price to $2 - Moomoo

Jun 03, 2026

Jun 03, 2026

HRTX Downgraded by Needham -- Outlook Adjusted to Hold - GuruFocus

Jun 03, 2026

Jun 03, 2026

Heron Therapeutics to Appeal Delaware Court Ruling Invalidating CINVANTI® Patents - Minichart

Jun 03, 2026

Jun 02, 2026

Why Did FULC, MVIS, HRTX Stocks Plunge To 52-Week Lows Today? - Stocktwits

Jun 02, 2026

Jun 02, 2026

CINVANTI patent claims invalidated as Heron Therapeutics (NASDAQ: HRTX) plans appeal - Stock Titan

Jun 02, 2026

Jun 02, 2026

Heron announces U.S. district court decision regarding Cinvanti patents - TipRanks

Jun 02, 2026

Jun 02, 2026

Heron Therapeutics loses patent case over Cinvanti drug - Investing.com UK

Jun 02, 2026

Jun 02, 2026

Heron Therapeutics loses patent case over Cinvanti drug By Investing.com - Investing.com India

Jun 02, 2026

Jun 02, 2026

U.S. District Court Issues Decision Regarding CINVANTI® Patents - GlobeNewswire

Jun 02, 2026

Jun 02, 2026

Court rules CINVANTI patents invalid; Heron readies appeal - Stock Titan

Jun 02, 2026

May 27, 2026

Heron outlines $173M-$183M 2026 net product sales outlook as it targets return to positive adjusted EBITDA - MSN

May 27, 2026

May 26, 2026

Number of shareholders of Heron Therapeutics, Inc. – NASDAQ:HRTX - TradingView

May 26, 2026

May 25, 2026

HRTX PE Ratio & Valuation, Is HRTX Overvalued - Intellectia AI

May 25, 2026

May 25, 2026

Heron Therapeutics (HRTX) Slides to $0.86 as Selling Pressure PersistsLinear Regression - newsline.com

May 25, 2026

May 24, 2026

Acute care revenue growth helps Heron (HRTX) reaffirm 2026 guidance despite Q1 sales decline - MSN

May 24, 2026

May 21, 2026

Heron Therapeutics (HRTX) Gains 3% as Biotech Stock Tests Key Resistance at $0.91Symmetrical Triangle - newsline.com

May 21, 2026

May 19, 2026

Why Heron Therapeutics, Inc. (HRTX) Price Target Was Reduced to $4 at H.C. Wainwright? - Insider Monkey

May 19, 2026

May 18, 2026

Heron Therapeutics (HRTX) price target decreased by 15.38% to 3.74 - MSN

May 18, 2026

May 16, 2026

Heron Therapeutics, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:HRTX) 2026-05-16 - Seeking Alpha

May 16, 2026

May 13, 2026

Adage Capital amendment shows 0% ownership in Heron Therapeutics (HRTX) - Stock Titan

May 13, 2026

May 12, 2026

H.C. Wainwright Maintains Heron Therapeutics(HRTX.US) With Buy Rating, Maintains Target Price $4 - Moomoo

May 12, 2026

May 12, 2026

Heron Therapeutics | 10-Q: Q1 2026 Earnings Report - Moomoo

May 12, 2026

May 12, 2026

Heron Therapeutics, Inc. (NASDAQ:HRTX) Q1 2026 Earnings Call Transcript - Insider Monkey

May 12, 2026

May 12, 2026

H.C. Wainwright Maintains Heron Therapeutics(HRTX.US) With Buy Rating, Cuts Target Price to $4 - Moomoo

May 12, 2026

May 12, 2026

Needham Maintains Heron Therapeutics(HRTX.US) With Buy Rating, Maintains Target Price $3 - Moomoo

May 12, 2026

May 12, 2026

H.C. Wainwright cuts Heron Therapeutics stock price target on weak Q1 results - Investing.com

May 12, 2026

May 12, 2026

TradingKey - TradingKey

May 12, 2026